Machine learning–based integration of network features and chemical structure of compounds for SARS‐CoV‐2 drug effect analysis

High drug development costs and the limited number of new annual drug approvals increase the need for innovative approaches for drug effect prediction. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the cause of coronavirus disease 2019 (COVID‐19), led to a global pandemic with high m...

Full description

Saved in:
Bibliographic Details
Published in:CPT: pharmacometrics and systems pharmacology 2024-02, Vol.13 (2), p.257-269
Main Authors: Späth, Julian, Wang, Rui‐Sheng, Humphrey, Maeve, Baumbach, Jan, Loscalzo, Joseph
Format: Article
Language:eng
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:High drug development costs and the limited number of new annual drug approvals increase the need for innovative approaches for drug effect prediction. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the cause of coronavirus disease 2019 (COVID‐19), led to a global pandemic with high morbidity and mortality. Although effective preventive measures exist, there are few effective treatments for hospitalized patients with SARS‐CoV‐2 infection. Drug repurposing and drug effect prediction are promising strategies that could shorten development time and reduce costs compared with de novo drug discovery. In this work, we present a machine learning framework to integrate a variety of target network features and physicochemical properties of compounds, and analyze their influence on the therapeutic effects for SARS‐CoV‐2 infection and on host cell cytotoxic effects. Random forest models trained on compounds with known experimental effects on SARS‐CoV‐2 infection and subsequent feature importance analysis based on Shapley values provided insights into the determinants of drug efficacy and cytotoxicity, which can be incorporated into novel drug discovery approaches. Given the complexity of molecular mechanisms of drug action and limited sample sizes, our models achieve a reasonable mean area under the receiver operating characteristic curve (ROC‐AUC) of 0.73 on an unseen validation set. To our knowledge, this is the first work to incorporate a combination of network and physicochemical features of compounds into a machine learning model to predict drug effects on SARS‐CoV‐2 infection. Our systems pharmacology–based machine learning framework can be used to classify other existing drugs for SARS‐CoV‐2 infection and can easily be adapted to drug effect prediction for future viral outbreaks.
ISSN:2163-8306
2163-8306